ANRO vs MNOV โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MNOV Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Growth & Margin, Options & Structure while ANRO counters with relative strength in Momentum & Technical. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MNOV at 8.5x Forward P/E and -1232.2% operating margin (+12.4% YoY). In options structure, ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANRO | MNOV | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.1B | $65.1M | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | 8.5x | Lower Multiple | MNOV |
| Forward P/E Ratio Valuation | N/M | 8.5x | Lower Multiple | MNOV |
| Revenue Growth (YoY) Growth | +0.0% | +12.4% | Higher Growth | MNOV |
| Operating Margin (TTM) Profitability | 0.0% | -1232.2% | Higher Margin | ANRO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -46.7% | -24.8% | Higher ROE | MNOV |
| 52-Week Range Position Momentum | 52% ($13โ$37) | 3% ($1โ$4) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 1.86ฮฒ ยท 91% Vol | 0.59ฮฒ ยท 38% Vol | Lower Realized Risk | MNOV |
| Unified Institutional Score Composite Signal | 45.8 / 100 (HOLD) | 50.2 / 100 (HOLD) | Higher Composite | MNOV |